These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 14586677

  • 21. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
    Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR.
    Kidney Int; 2004 May; 65(5):1914-26. PubMed ID: 15086935
    [Abstract] [Full Text] [Related]

  • 22. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.
    Russell R, Brookshire MA, Zekonis M, Moe SM.
    Clin Nephrol; 2002 Sep; 58(3):238-43. PubMed ID: 12356195
    [Abstract] [Full Text] [Related]

  • 23. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R, Naito S, Inagaki Y, Hata T, Ishida Y, Chida Y, Takayama M, Tachibana K, Ohtsuka M, Inoue A.
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [Abstract] [Full Text] [Related]

  • 24. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 25. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
    Ramos R, Moreso F, Borras M, Ponz E, Buades JM, Teixidó J, Morey A, Garcia C, Vera M, Doñate MT, de Arellano MR, Barbosa F, González MT.
    Perit Dial Int; 2007 Aug; 27(6):697-701. PubMed ID: 17984434
    [Abstract] [Full Text] [Related]

  • 26. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.
    Ren Fail; 2006 Aug; 28(8):701-7. PubMed ID: 17162430
    [Abstract] [Full Text] [Related]

  • 27. Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.
    Paret CL.
    J Ren Nutr; 2003 Oct; 13(4):288-94. PubMed ID: 14566766
    [Abstract] [Full Text] [Related]

  • 28. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.
    McIntyre CW, Patel V, Taylor GS, Fluck RJ.
    Nephrol Dial Transplant; 2002 Sep; 17(9):1643-8. PubMed ID: 12198217
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 30. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [Abstract] [Full Text] [Related]

  • 32. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB, Smeeding JE, Brook RA.
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [Abstract] [Full Text] [Related]

  • 33. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M.
    Drug Saf; 2003 Jul; 26(15):1093-115. PubMed ID: 14640773
    [Abstract] [Full Text] [Related]

  • 34. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.
    Amin N.
    Nephrol Dial Transplant; 2002 Feb; 17(2):340-5. PubMed ID: 11812903
    [Abstract] [Full Text] [Related]

  • 35. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
    Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group.
    Kidney Int; 2002 Jul; 62(1):245-52. PubMed ID: 12081584
    [Abstract] [Full Text] [Related]

  • 36. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [Abstract] [Full Text] [Related]

  • 37. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients.
    Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernández E.
    Nephron; 2002 Oct; 92(2):499-500. PubMed ID: 12218343
    [No Abstract] [Full Text] [Related]

  • 38. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
    Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA.
    Ren Fail; 2005 Oct; 27(2):143-7. PubMed ID: 15807177
    [Abstract] [Full Text] [Related]

  • 39. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR, Qunibi WY.
    Kidney Int Suppl; 2005 Jun; (95):S13-20. PubMed ID: 15882308
    [Abstract] [Full Text] [Related]

  • 40. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.